drugset / Trial / NCT05694819
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.
Timeline
- Start
- 2020-04-17
- Primary completion
- 2024-08-09
- Completion
- 2026-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darolutamide | Other / unclassified | 600 mg | Oral |
| Subject | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |